Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study
The study demonstrates high acceptance and favorable outcomes for switching to ADA biosimilars in IBD patients, including sustained efficacy and good treatment persistence. These findings suggest that switching to ADA biosimilars is a viable option for IBD patients, with positive results in terms of both clinical effectiveness and patient adherence.
Authors
- Pauline Wils (ORCID: https://orcid.org/0000-0002-7684-6067)
- Nicolas Duveau
- Sofia Hambli
- Pierre Desreumaux (ORCID: https://orcid.org/0000-0002-6127-5281)
- Maria Nachury (ORCID: https://orcid.org/0000-0001-9583-8946)
- Romain Gérard (ORCID: https://orcid.org/0000-0003-4674-7444)
- Aurélie Blondeaux
- Gabrielle D’Abbundo
- Alice Wartski
Institutions
- Inserm (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier de Roubaix (FR)
- Hôpital Claude Huriez (FR)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1177/17562848251332025
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.59